

ASX Announcement
5 September 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX: OIL)

Optiscan Despatches Entitlement Offer Documents to Eligible Shareholders

Optiscan has despatched documents to Shareholders for its fully underwritten pro-rata renounceable entitlement offer to raise \$17.75m to fund the next stage of its strategic transformation to a medical device manufacturer and digital healthcare solution provider.

Optiscan Imaging Limited (ASX: OIL) ('Optiscan' or the '**Company**') is pleased to announce that in accordance with the indicative timetable, the Company has today despatched the Prospectus and personalised Entitlement and Acceptance Form to Eligible Shareholders in relation to the Offer.

As announced on 27 August 2025, the Company is undertaking a fully underwritten pro-rata renounceable entitlement offer of one (1) fully paid ordinary share (**Share**) for every four (4) Shares held on the record date of 2 September 2025 (**Record Date**) (**Offer**) under a prospectus lodged with ASX and ASIC on 27 August 2025 (**Prospectus**). The Offer will raise approximately \$17,750,992 by the issue of 208,835,201 Shares in the capital of the Company at an issue price of \$0.085 per Share.

Shareholders are advised that the Offer under the Prospectus is now open for subscription. Eligible Shareholders who have a registered address within Australia, New Zealand or Singapore and who hold shares on the Record Date (**Eligible Shareholders**) can access their personalised Entitlement and Acceptance Form online at www.computersharecas.com.au/oiloffer.

Ineligible Shareholders have been sent notices providing them with details of the Offer and advising them they will not be offered shares pursuant to the Offer.

Eligible Shareholders are encouraged to carefully consider the Prospectus in deciding whether to subscribe for Shares under the Offer and will need to follow the instructions on the Entitlement and Acceptance Form that will accompany the Prospectus.

The Closing Date of the Offer is **5:00pm (AEST) on Tuesday, 16 September 2025** (unless extended).

Key Offer Terms

	FULL SUBSCRIPTION (\$17,750,992)
Offer Price per Share	\$0.085
Entitlement Ratio (based on existing Shares)	1:4
Shares currently on issue	835,340,803
Shares to be issued under the Offer	208,835,201
Gross proceeds of the issue of Shares	\$17,750,992
Shares on issue Post-Offer	1,044,176,004

Key Dates

Lodgement of Prospectus with the ASIC	Wednesday, 27 August 2025
Lodgement of Prospectus and Appendix 3B with ASX	Wednesday, 27 August 2025
Ex date	Monday, 1 September 2025
Rights start trading	Monday, 1 September 2025
Record Date for determining Entitlements	Tuesday, 2 September 2025
Offer opening date, Prospectus sent out to Shareholders and Company announces this has been completed	Friday, 5 September 2025
Rights stop trading	Tuesday, 9 September 2025
Shares quoted on a deferred settlement basis	Wednesday, 10 September 2025
Last day to extend the Closing Date (before noon AEST)	Thursday, 11 September 2025
Closing Date as at 5:00pm* of Offer and Shortfall Offer	Tuesday, 16 September 2025
ASX and Underwriter notified of under subscriptions	Thursday, 18 September 2025
Underwriter subscribes for Shortfall under terms of Underwriting Agreement	Monday, 22 September 2025
Issue date and lodgement of Appendix 2A with ASX applying for quotation of the Shares	Tuesday, 23 September 2025

All dates and times are indicative only and subject to change. The Company reserves the right to withdraw the Offer or amend all or any of these dates and times without notice, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and other applicable laws.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

Optiscan Imaging Ltd (ASX:OIL)

16 Miles St, Mulgrave VIC 3170, Australia • www.optiscan.com • ABN: 81 077 771 987

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.